X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12645) 12645
Book Chapter (68) 68
Dissertation (62) 62
Publication (25) 25
Magazine Article (12) 12
Conference Proceeding (6) 6
Newspaper Article (2) 2
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7534) 7534
braf (6519) 6519
oncology (4831) 4831
mutation (4402) 4402
cancer (3741) 3741
melanoma (3740) 3740
female (3596) 3596
male (3378) 3378
proto-oncogene proteins b-raf - genetics (3248) 3248
middle aged (2814) 2814
braf mutation (2292) 2292
aged (2288) 2288
adult (2269) 2269
tumors (2026) 2026
pathology (1829) 1829
braf mutations (1579) 1579
prognosis (1570) 1570
genetic aspects (1567) 1567
colorectal cancer (1513) 1513
metastasis (1483) 1483
mutations (1394) 1394
vemurafenib (1382) 1382
melanoma - genetics (1334) 1334
survival (1298) 1298
gene mutations (1272) 1272
metastatic melanoma (1255) 1255
carcinoma (1243) 1243
expression (1243) 1243
kras (1241) 1241
animals (1236) 1236
cell biology (1176) 1176
melanoma - pathology (1168) 1168
aged, 80 and over (1110) 1110
research (1110) 1110
melanoma - drug therapy (1100) 1100
analysis (1096) 1096
cell line, tumor (1079) 1079
thyroid cancer (1079) 1079
immunohistochemistry (1055) 1055
microsatellite instability (1055) 1055
thyroid neoplasms - genetics (1027) 1027
neoplasms (1025) 1025
care and treatment (1008) 1008
colorectal neoplasms - genetics (991) 991
dermatology (930) 930
kinases (908) 908
thyroid neoplasms - pathology (907) 907
chemotherapy (876) 876
surgery (856) 856
dna mutational analysis (845) 845
diagnosis (844) 844
activation (837) 837
proto-oncogene proteins b-raf - metabolism (812) 812
antineoplastic agents - therapeutic use (784) 784
proto-oncogene proteins b-raf - antagonists & inhibitors (768) 768
gene (760) 760
resistance (754) 754
endocrinology & metabolism (748) 748
colorectal neoplasms - pathology (743) 743
braf v600e mutation (741) 741
young adult (739) 739
skin neoplasms - pathology (730) 730
open-label (719) 719
pathway (719) 719
biomarkers, tumor - genetics (717) 717
immunotherapy (702) 702
patients (699) 699
therapy (698) 698
health aspects (696) 696
medicine & public health (677) 677
mice (673) 673
skin neoplasms - genetics (673) 673
adolescent (662) 662
biochemistry & molecular biology (653) 653
retrospective studies (652) 652
digestive system diseases (651) 651
signal transduction (645) 645
targeted therapy (630) 630
gene expression (624) 624
proteins (622) 622
ras proteins - genetics (621) 621
malignant-melanoma (620) 620
acquired-resistance (619) 619
mutation - genetics (618) 618
medicine, research & experimental (613) 613
b-raf (605) 605
dabrafenib (604) 604
metastases (604) 604
treatment outcome (598) 598
neoplasm staging (582) 582
apoptosis (580) 580
colon-cancer (579) 579
inhibition (574) 574
genes (573) 573
papillary thyroid carcinoma (564) 564
dna methylation (563) 563
development and progression (562) 562
melanoma - metabolism (551) 551
protein kinase inhibitors - pharmacology (542) 542
phenotype (523) 523
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12240) 12240
Chinese (207) 207
French (149) 149
German (147) 147
Spanish (54) 54
Japanese (46) 46
Russian (40) 40
Korean (31) 31
Czech (24) 24
Portuguese (18) 18
Polish (14) 14
Hungarian (7) 7
Norwegian (7) 7
Turkish (6) 6
Dutch (3) 3
Italian (3) 3
Slovenian (2) 2
Swedish (2) 2
Croatian (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC cancer, ISSN 1471-2407, 01/2014, Volume 14, Issue 1, pp. 13 - 13
Journal Article
International journal of cancer, ISSN 0020-7136, 05/2011, Volume 128, Issue 9, pp. 2075 - 2084
BRAFV600E mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug... 
prognosis | BRAF | colorectal cancer | Prognosis | Colorectal cancer
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2014, Volume 50, Issue 3, pp. 611 - 621
Abstract Background & Aim Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase... 
Hematology, Oncology and Palliative Medicine | Vemurafenib | Symptomatic brain metastases | Tumour regression | BRAF inhibitor | Safety | Advanced melanoma | BRAF mutation
Journal Article
Cancer, ISSN 0008-543X, 2014, Volume 120, Issue 22, pp. 3446 - 3456
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple... 
mitogen‐activated protein kinase (MAPK) | mitogen‐activated protein kinase‐kinase (MEK) | signaling | colorectal cancer | ovarian cancer | v‐raf murine sarcoma viral oncogene homolog (BRAF) | melanoma | extracellular signal‐regulated kinase (ERK) | Extracellular signal-regulated kinase (ERK) | Signaling | V-raf murine sarcoma viral oncogene homolog (BRAF) | Colorectal cancer | Melanoma | Mitogen-activated protein kinase (MAPK) | Mitogen-activated protein kinase-kinase (MEK) | Ovarian cancer | mitogen-activated protein kinase-kinase (MEK) | mitogen-activated protein kinase (MAPK) | v-raf murine sarcoma viral oncogene homolog (BRAF) | extracellular signal-regulated kinase (ERK) | RNA INTERFERENCE SCREEN | ACTIVATED PROTEIN-KINASE | BRAF(V600E) INHIBITION | ACQUIRED-RESISTANCE | POTENTIAL MECHANISM | TUMOR HETEROGENEITY | CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | SIGNALING PATHWAY | BRAF MUTATIONS | Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | MAP Kinase Signaling System - physiology | Animals | MAP Kinase Signaling System - drug effects | Protein Kinase Inhibitors - therapeutic use | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - physiology | Calcium Signaling | Neoplasms - drug therapy | Care and treatment | Usage | Rapamycin | Protein kinases | Health aspects | Tumors | MEK | BRAF | MAPK | ERK
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 8, pp. 1333 - 1344
BACKGROUND Optimal treatments for vulvar and vaginal melanomas (VVMs) have not been identified. Herein, the authors compare molecular profiles between VVM and... 
genitourinary melanoma | gene profiling | vulvar melanoma | KIT proto‐oncogene receptor tyrosine kinase (KIT) mutation | mucosal melanoma | B‐Raf proto‐oncogene serine/threonine kinase (BRAF) mutation | molecular targets | vaginal melanoma | neuroblastoma rat sarcoma (NRAS) mutation | KIT proto-oncogene receptor tyrosine kinase (KIT) mutation | B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation | threonine kinase (BRAF) mutation | B-Raf proto-oncogene serine | MALIGNANT-MELANOMA | DACARBAZINE | TUMORS | ONCOLOGY | KIT GENE-MUTATIONS | BRAF MUTATIONS | UNCOMMON | EXPRESSION | IPILIMUMAB | Immunohistochemistry | Melanoma - diagnosis | Humans | Middle Aged | Male | Gene Expression Profiling | Biomarkers, Tumor | Vaginal Neoplasms - genetics | Young Adult | Melanoma - genetics | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Vulvar Neoplasms - diagnosis | In Situ Hybridization, Fluorescence | Mucous Membrane - metabolism | Mucous Membrane - pathology | Vulvar Neoplasms - genetics | Proto-Oncogene Proteins B-raf - genetics | Aged | High-Throughput Nucleotide Sequencing | Mutation | Neoplasm Staging | Vaginal Neoplasms - diagnosis | Usage | Care and treatment | Gene mutations | Vulvar cancer | Genetic aspects | Research | Biological markers | Drugs | PD-1 protein | Estrogens | Mucosa | Clinical trials | Raf protein | Alkylation | Skin cancer | Platinum | Immunotherapy | Medical research | Threonine | Melanoma | Vagina | Gene expression | Sensitivity | Reviews | Anthracycline | Valine | PD-L1 protein | Biomarkers | ERCC1 protein | Protein-serine/threonine kinase | Progesterone | Tumors | Cancer
Journal Article
Journal Article